Parker Waichman Sues Novo Nordisk Over Wegovy Vision Loss, Citing 7-Fold NAION Risk
Updated
Updated · PR Newswire · May 22
Parker Waichman Sues Novo Nordisk Over Wegovy Vision Loss, Citing 7-Fold NAION Risk
1 articles · Updated · PR Newswire · May 22
Summary
May 8 filings included a Florida plaintiff who says Wegovy caused NAION, an irreversible optic-nerve condition that can leave partial or complete permanent blindness.
Parker Waichman said it has now filed multiple lawsuits over Ozempic and Wegovy, alleging Novo Nordisk failed to warn patients and doctors about the eye-risk.
A 2025 JAMA Ophthalmology study reviewed nine GLP-1 users with optic-nerve disorders, while Mass Eye and Ear research found semaglutide users faced sharply higher NAION risk.
That research said diabetic semaglutide users were 4 times more likely to develop NAION, and non-diabetic weight-loss users faced a 7-fold increased risk.
The litigation adds to scrutiny of blockbuster GLP-1 drugs originally developed for Type 2 diabetes but now widely used for weight loss.